Disease relevance of Alveolar Bone Loss

• This observation indicates that arachidonic acid metabolites are important in the alveolar bone loss of periodontitis and suggests a use for flurbiprofen in the management of bone resorption disease [1].
• Other factors, such as occlusal trauma and gingivitis, may play some role in alveolar bone loss [2].
• The aim of this study was to determine whether the non-steroidal anti-inflammatory drug, flurbiprofen, which has been shown to be an inhibitor of alveolar bone loss in human periodontal disease, is present in human crevicular fluid (CF) following oral dosing [3].
• RESULTS: Histological examination and determination of bone mineral density in the interdental alveolar bone area between M1 and M2 revealed that placement of an elastic ring caused severe vertical and horizontal bone resorption on the control side, while the topical administration of clodronate significantly prevented such alveolar bone loss [4].
• In the present study, we tested the hypothesis that endogenous interleukin-10 is a potent suppressor of Porphyromonas gingivalis-induced alveolar bone loss in vivo [5].

High impact information on Alveolar Bone Loss

• There was no significant difference in periodontal bone loss between animals immunized with formalin-killed whole cells and those immunized with RgpA-Kgp [6].
• In conclusion, P-selectin and ICAM-1 deficiencies increase susceptibility to and severity of alveolar bone loss after P. gingivalis infection [7].
• Immune response, gingival inflammation, and periodontal bone loss were examined in these animals [8].
• Thus, the implant-abutment interface dictates the intensity and location of peri-implant inflammatory cell accumulation, a potential contributing component in the extent of implant-associated alveolar bone loss [9].
• The role of inducible nitric oxide synthase (iNOS) in bone development and bacterially induced periodontal bone loss was examined using mice with targeted mutation of the iNOS gene [10].

Chemical compound and disease context of Alveolar Bone Loss

• Estimation of age at death was made by a combination of dental developmental staging for younger individuals and occlusal attrition and/or alveolar bone loss in adults [11].
• Tannerella forsythia-induced alveolar bone loss in mice involves leucine-rich-repeat BspA protein [12].
• Alveolar bone loss associated with glucose tolerance in Japanese men [13].
• Effectiveness of local delivery of alendronate in reducing alveolar bone loss following periodontal surgery in rats [14].
• Altering the progression of human alveolar bone loss with the non-steroidal anti-inflammatory drug flurbiprofen [15].

Biological context of Alveolar Bone Loss

• RESULTS: The results of the study showed that postmenopausal women on estrogen therapy had more alveolar bone loss, more missing teeth, and reduced alveolar and second metacarpal bone density than premenopausal women [16].
• Nuclear medicine was used to assess the activity of alveolar bone loss in beagle dogs treated with the nonsteroidal anti-inflammatory drug flurbiprofen [17].
• With only partial compliance to local debridement, chlorhexidine oral rinses, and systemic metronidazole therapy, alveolar bone loss resulted in tooth mobility necessitating extraction of 2 involved teeth [18].
• CONCLUSIONS: The above results suggest that pregnancy and subsequent lactation could be risk factors for alveolar bone loss, especially under conditions of Ca insufficiency or deficiency and that Ca insufficiency or deficiency in the mother caused decreases in the BMD of alveolar bone in the pups [19].
• However, it is unclear whether VDR genotypes could be associated with alveolar bone loss of patients with periodontitis, or whether vitamin D receptor gene could be a candidate gene for susceptibility to periodontitis [20].

Anatomical context of Alveolar Bone Loss

• On the other hand, the radiographic data showed that cyclosporin A therapy diminished the alveolar bone loss at the mesial surface of the lower first molars [21].
• Nicotine-modulated osteoclast stimulation may, in part, explain the increased rapidity of periodontal bone loss and refractory disease incidence in smokers [22].
• In the present study, we compared the alveolar bone loss after mucoperiosteal flap surgery by a coronal approach (COR) to a surgical approach incising the mucosa close to the tooth apices and separating the mucoperiosteum toward the tooth crown (apical approach, AP) [23].
• Among the black JP subjects with radiographs of the mixed dentition, 85.7% presented evidence of bone loss, and of those with radiographs of the deciduous dentition, 71.4% had discernible alveolar bone loss [24].
• Localized juvenile periodontitis patients exhibiting first molar and incisor alveolar bone loss and with large numbers of A actinomycetemcomitans in deep periodontal pockets were included in this study [25].

Gene context of Alveolar Bone Loss

• Although interleukin-1beta was marginally increased, blockade of both interleukin-1 isoforms or interleukin-1 receptor type I with neutralizing antisera failed to reduce alveolar bone loss in interleukin-10(-/-) mice, indicating the operation of an interleukin-1-independent mechanism [5].
• The total amount of IL-1 alpha, IL-1 beta and the IL-1AI, but not total IL-1ra, were found to be correlated with alveolar bone loss score [26].
• The expression of MMPs (MMP-1, 2 and 9) and RANKL was correlated with the expression of interleukin-1beta, tumor necrosis factor-alpha and interferon-gamma, in a time period characterized by the intense increase of inflammatory reaction and alveolar bone loss [27].
• Alveolar bone loss in active sites correlated with increased GCF levels of IL-1 beta and IL-2 [28].
• Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modified tetracyclines [29].

Analytical, diagnostic and therapeutic context of Alveolar Bone Loss

• BACKGROUND: We examined whether topical administration of a bisphosphonate clodronate could prevent alveolar bone loss in rats with experimental periodontitis [4].
• Effect of low-protein diet on alveolar bone loss in streptozotocin-induced diabetic rats [30].
• The objective of this double-blind study was to evaluate alendronate inhibition of alveolar bone loss in the naturally occurring beagle dog model of periodontitis [31].
• Peri-implant alveolar bone loss with respect to bone quality after use of the osteotome technique: results of a retrospective study [32].
• The criteria were based on the mean marginal alveolar bone loss, the placement of prosthesis of satisfactory appearance, and the absence of implant mobility, peri-implant radiolucency, pain, discomfort or infection [33].

References